STAR.NS
Strides Pharma Science Limited [STAR.NS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
STAR.NS Stock Summary
Top 10 Correlated ETFs
STAR.NS
Top 10 Correlated Stocks
STAR.NS
In the News
STAR.NS Financial details
Company Rating
Neutral
Market Cap
77.19B
Income
-1.03B
Revenue
39.53B
Book val./share
-
Cash/share
-
Dividend
1.5
Dividend %
0.22%
Employees
2.85K
Optionable
No
Shortable
Yes
Earnings
23 May 2024
P/E
-26.67
Forward P/E
-
PEG
3.97
P/S
1.68
P/B
3.04
P/C
-
P/FCF
4887.39
Quick Ratio
0.63
Current Ratio
1.08
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-17.35
EPS next Y
-
EPS next Q
-
EPS this Y
-51.5%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
4.61%
Revenue Q/Q
3.83%
EPS Q/Q
-96.63%
-
-
-
-
SMA20
5.53%
SMA50
22.13%
SMA100
72.28%
Inst Own
-
Inst Trans
-
ROA
-4%
ROE
-22%
ROC
0.07%
Gross Margin
58%
Oper. Margin
6%
Profit Margin
-6%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
306.0-865.0
52W High
-2.33%
52W Low
+176.09%
RSI
62
Rel Volume
0.31
Avg Volume
563.52K
Volume
174.42K
Perf Week
-0.19%
Perf Month
5.63%
Perf Quarter
74.03%
Perf Half Y
65.45%
-
-
-
-
Beta
0.776
-
-
Volatility
4.36%, 28.55%
Prev Close
0.64%
Price
844.85
Change
1.92%
STAR.NS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-03-31
| Metric | History | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 328.74 | 296.67 | 362.81 | 336.73 | 409.45 | |
| Net income per share | 36.25 | 4.06 | 29.96 | -52.84 | -25.63 | |
| Operating cash flow per share | 6.71 | 22.87 | 53.73 | -28.73 | 4.93 | |
| Free cash flow per share | -30.04 | 6.12 | 20.53 | -44.7 | -5.61 | |
| Cash per share | 88.49 | 38.84 | 30.67 | 20.52 | 50.91 | |
| Book value per share | 295.78 | 282.23 | 309.86 | 262.87 | 245.59 | |
| Tangible book value per share | -14.75 | 180.88 | 191.38 | 141.78 | 121.67 | |
| Share holders equity per share | 295.78 | 282.23 | 309.86 | 262.87 | 245.59 | |
| Interest debt per share | 379.59 | 252.93 | 276.9 | 353.3 | 365.31 | |
| Market cap | 42.64B | 28.85B | 75.69B | 31.11B | 25.79B | |
| Enterprise value | 71.28B | 49.37B | 97.92B | 59.65B | 53.06B | |
| P/E ratio | 13.13 | 79.28 | 28.2 | -6.56 | -11.17 | |
| Price to sales ratio | 1.45 | 1.09 | 2.33 | 1.03 | 0.7 | |
| POCF ratio | 71 | 14.09 | 15.72 | -12.07 | 58.08 | |
| PFCF ratio | -15.85 | 52.66 | 41.15 | -7.75 | -51.05 | |
| P/B Ratio | 1.61 | 1.14 | 2.73 | 1.32 | 1.17 | |
| PTB ratio | 1.61 | 1.14 | 2.73 | 1.32 | 1.17 | |
| EV to sales | 2.42 | 1.86 | 3.01 | 1.97 | 1.44 | |
| Enterprise value over EBITDA | 19.91 | 12.47 | 14.76 | -120.72 | 32.44 | |
| EV to operating cash flow | 118.69 | 24.11 | 20.34 | -23.14 | 119.46 | |
| EV to free cash flow | -26.5 | 90.12 | 53.23 | -14.87 | -105 | |
| Earnings yield | 0.08 | 0.01 | 0.04 | -0.15 | -0.09 | |
| Free cash flow yield | -0.06 | 0.02 | 0.02 | -0.13 | -0.02 | |
| Debt to equity | 1.22 | 0.88 | 0.85 | 1.28 | 1.37 | |
| Debt to assets | 0.4 | 0.36 | 0.33 | 0.43 | 0.46 | |
| Net debt to EBITDA | 8 | 5.18 | 3.35 | -57.76 | 16.67 | |
| Current ratio | 1.13 | 0.93 | 1.03 | 0.99 | 1.08 | |
| Interest coverage | 1.74 | 6.84 | 3.43 | -1.94 | -0.31 | |
| Income quality | 0.17 | 4.22 | 1.66 | 0.4 | -0.17 | |
| Dividend Yield | 0 | 0.05 | 0 | 0.01 | 0 | |
| Payout ratio | 0.06 | 4.23 | 0.07 | -0.05 | 0 | |
| Sales general and administrative to revenue | 0.04 | 0.04 | 0.04 | 0.05 | 0.04 | |
| Research and developement to revenue | 0.04 | 0.04 | 0.03 | 0.03 | 0.02 | |
| Intangibles to total assets | 0.37 | 0.16 | 0.16 | 0.16 | 0.16 | |
| Capex to operating cash flow | -5.48 | -0.73 | -0.62 | 0.56 | -2.14 | |
| Capex to revenue | -0.11 | -0.06 | -0.09 | -0.05 | -0.03 | |
| Capex to depreciation | -1.91 | -0.8 | -1.44 | -0.62 | -0.39 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 491.18 | 160.64 | 457.01 | 559.06 | 376.35 | |
| ROIC | 0.04 | 0.03 | 0.08 | -0.04 | -0.01 | |
| Return on tangible assets | 0.06 | 0.01 | 0.05 | -0.08 | -0.04 | |
| Graham Net | -334.8 | -232.44 | -275.92 | -274.59 | -263.34 | |
| Working capital | 3.44B | -1.7B | 814.64M | -472.66M | 2.53B | |
| Tangible asset value | -1.32B | 16.2B | 17.15B | 12.72B | 10.96B | |
| Net current asset value | -21.56B | -11.82B | -13.81B | -12.28B | -12.22B | |
| Invested capital | 1.22 | 0.88 | 0.85 | 1.28 | 1.37 | |
| Average receivables | 12.6B | 11.43B | 10.6B | 14.74B | 16.12B | |
| Average payables | 8.03B | 8.46B | 9.88B | 11.25B | 10.27B | |
| Average inventory | 7.11B | 8.27B | 9.92B | 11.87B | 11.6B | |
| Days sales outstanding | 161.69 | 134.9 | 127.73 | 218.54 | 140.06 | |
| Days payables outstanding | 217.01 | 245.93 | 305.37 | 247.02 | 220.39 | |
| Days of inventory on hand | 211.3 | 241.24 | 311.09 | 270.6 | 257.22 | |
| Receivables turnover | 2.26 | 2.71 | 2.86 | 1.67 | 2.61 | |
| Payables turnover | 1.68 | 1.48 | 1.2 | 1.48 | 1.66 | |
| Inventory turnover | 1.73 | 1.51 | 1.17 | 1.35 | 1.42 | |
| ROE | 0.12 | 0.01 | 0.1 | -0.2 | -0.1 | |
| Capex per share | -36.75 | -16.75 | -33.2 | -15.98 | -10.54 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q3
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 95.77 | 109.23 | 102.99 | 110.64 | 113.45 | |
| Net income per share | -9.09 | -1.53 | -0.79 | -14.54 | 5.43 | |
| Operating cash flow per share | 13.34 | 0.14 | 13.2 | 13.31 | 11.2 | |
| Free cash flow per share | 13.34 | 0.14 | 13.2 | 13.31 | 11.2 | |
| Cash per share | 0 | 50.78 | 0 | 47.93 | 0 | |
| Book value per share | 0 | 244.98 | 0 | 227.33 | 0 | |
| Tangible book value per share | 0 | 121.37 | 0 | 104.13 | 0 | |
| Share holders equity per share | 0 | 244.98 | 0 | 227.33 | 0 | |
| Interest debt per share | 6.47 | 344.41 | 8.46 | 318.07 | 8.67 | |
| Market cap | 31.59B | 25.86B | 38.89B | 45.9B | 59.84B | |
| Enterprise value | 31.59B | 53.12B | 38.89B | 72.86B | 59.84B | |
| P/E ratio | -9.62 | -46.86 | -136.68 | -8.74 | 30.12 | |
| Price to sales ratio | 3.65 | 2.62 | 4.18 | 4.59 | 5.77 | |
| POCF ratio | 26.23 | 1.99K | 32.63 | 38.18 | 58.41 | |
| PFCF ratio | 26.23 | 1.99K | 32.63 | 38.18 | 58.41 | |
| P/B Ratio | 0 | 1.17 | 0 | 2.24 | 0 | |
| PTB ratio | 0 | 1.17 | 0 | 2.24 | 0 | |
| EV to sales | 3.65 | 5.39 | 4.18 | 7.29 | 5.77 | |
| Enterprise value over EBITDA | 133.27 | 37.44 | 27.83 | 49.31 | 37.7 | |
| EV to operating cash flow | 26.23 | 4.08K | 32.63 | 60.61 | 58.41 | |
| EV to free cash flow | 26.23 | 4.08K | 32.63 | 60.61 | 58.41 | |
| Earnings yield | -0.03 | -0.01 | 0 | -0.03 | 0.01 | |
| Free cash flow yield | 0.04 | 0 | 0.03 | 0.03 | 0.02 | |
| Debt to equity | 0 | 1.37 | 0 | 1.36 | 0 | |
| Debt to assets | 0 | 0.46 | 0 | 0.44 | 0 | |
| Net debt to EBITDA | 0 | 19.22 | 0 | 18.25 | 0 | |
| Current ratio | 0 | 1.08 | 0 | 1.08 | 0 | |
| Interest coverage | -0.62 | 1.01 | 1.05 | 1.12 | 1.36 | |
| Income quality | -1.51 | -0.14 | -16.76 | -0.92 | -22.86 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0.24 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0.07 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0.16 | 0 | 0.17 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0 | 91.76 | 0 | 272.71 | 0 | |
| ROIC | 0 | 0.03 | 0 | 0.02 | 0 | |
| Return on tangible assets | 0 | 0 | 0 | -0.02 | 0 | |
| Graham Net | 0 | -262.7 | 0 | -241.29 | 0 | |
| Working capital | 1.27B | 2.53B | 3.67B | 2.51B | 0 | |
| Tangible asset value | 0 | 10.96B | 0 | 9.41B | 0 | |
| Net current asset value | 1.27B | -12.22B | 3.67B | -9.55B | 0 | |
| Invested capital | 0 | 1.37 | 0 | 1.36 | 0 | |
| Average receivables | 6.04B | 7.08B | 7.08B | 7.75B | 7.75B | |
| Average payables | 4.83B | 4.91B | 4.91B | 4.7B | 4.7B | |
| Average inventory | 5.67B | 5.73B | 5.73B | 5.69B | 5.69B | |
| Days sales outstanding | 0 | 129.14 | 0 | 139.62 | 0 | |
| Days payables outstanding | 0 | 220.64 | 0 | 202.51 | 0 | |
| Days of inventory on hand | 0 | 257.51 | 0 | 244.89 | 0 | |
| Receivables turnover | 0 | 0.7 | 0 | 0.64 | 0 | |
| Payables turnover | 0 | 0.41 | 0 | 0.44 | 0 | |
| Inventory turnover | 0 | 0.35 | 0 | 0.37 | 0 | |
| ROE | 0 | -0.01 | 0 | -0.06 | 0 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
STAR.NS Frequently Asked Questions
What is Strides Pharma Science Limited stock symbol ?
Strides Pharma Science Limited is a IN stock and trading under the symbol STAR.NS
What is Strides Pharma Science Limited stock quote today ?
Strides Pharma Science Limited stock price is $844.85 today.
Is Strides Pharma Science Limited stock public?
Yes, Strides Pharma Science Limited is a publicly traded company.
Something similar
Company Profile
- Volume Average 563.52K
- Market Capitalization 77.19B
- Employee 2.85K
- CEO Mr. Arun Kumar Pillai B.Com.
- Headquarters Bengaluru,IN
- IPO Date 2002-06-26
-
Website
https://www.strides.com 
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally. It operates through two segments, Pharmaceutical and Biopharmaceutical. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. Strides Pharma Science Limited was incorporated in 1990 and is headquartered in Bengaluru, India.
